Personalis
Update in progressPSNL (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
Personalis, Inc. develops and sells cancer genomic tests and related services in the U.S. and internationally. It offers NeXT Personal, a tumor-informed liquid biopsy for detecting minimal residual disease, therapy response, and recurrence; ImmunoID NeXT, a tissue-based assay combining whole exome and transcriptome data to profile the tumor and its microenvironment; NeXT Personal Dx; and NeXT Dx for therapy guidance and trial matching. It also performs whole exome sequencing with matched blood and whole genome sequencing for research. Customers include pharma, diagnostics, universities, non-profits, government, and patients. A collaboration with Tempus AI expands colorectal cancer testing. Incorporated 2011, headquartered in Fremont, California.
Company score
- Sentiment
- -0.06
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.17
- Governance
- -0.24
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.08
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!